India's aesthetic devices market is experiencing remarkable expansion, with the sector valued at approximately ₹7,100 crore ($870 million) in 2026 and projected to reach ₹14,000 crore ($1.73 billion) by 2031. According to a report by research firm Mordor Intelligence, this represents a compound annual growth rate (CAGR) of nearly 15 per cent. The body-contouring and skin-tightening segment is emerging as one of the fastest-growing categories, with these devices projected to grow at an annual rate of around 17 per cent, outpacing other aesthetic procedures such as laser hair removal.
The growth is primarily attributed to the rising adoption of GLP-1 weight-loss medicines, including Ozempic, Wegovy and Mounjaro, which contain active ingredients such as semaglutide and tirzepatide. As reported by Mordor Intelligence, while these drugs help users lose significant weight, rapid weight loss can lead to loose skin, reduced facial volume and uneven fat distribution, prompting patients to seek aesthetic procedures. The trend is gaining global recognition, with the American Society of Plastic Surgeons identifying 'GLP-1 makeovers' as one of the key procedural trends for 2026, after reporting that its members treated more than 837,000 patients using these medicines in 2024.
According to research firm IMARC Group, India's broader medical aesthetics market was worth around ₹5,250 crore ($650 million) in 2025, supported by rising demand for minimally invasive procedures among working professionals and growing interest from male consumers. The report notes that non-invasive body contouring procedures are generally intended for people who have already achieved significant weight loss and are looking to improve body shape rather than lose additional weight. Dr. D. Vijaya Krishna, Founder and Chairman of Kolors Healthcare, emphasized that non-invasive body contouring is not intended as a substitute for weight-loss programmes, but rather designed for people close to their target weight who want to address specific areas after weight loss.
The report highlights significant regulatory challenges facing the industry, noting that while aesthetic devices fall under the Central Drugs Standard Control Organisation (CDSCO) medical device framework, oversight of clinics and operator qualifications remains inconsistent across the country. According to the report, body-contouring procedures have limitations as these devices are meant to reshape specific areas rather than deliver substantial weight reduction, with treatment outcomes depending on factors such as patient selection and planning. Despite these challenges, the global expansion of GLP-1 weight-loss medicine use is expected to continue driving demand for post-weight-loss aesthetic procedures.
